ChemCodes, a chemistry driven drug discovery company, has negotiated an expanded technology license agreement with the pharmaceutical company GlaxoSmithKline.
The new agreement extends a previous agreement centered exclusively on chemistry to include biological screening processes. This new license will allow ChemCodes to fully leverage its technology platform for drug discovery, the company says.
“ChemCodes has had a long-standing licensing relationship with GlaxoSmithKline and we are delighted to extend this agreement to allow full application of the proprietary chemistry platform,” Robert Bell, chief executive officer of ChemCodes, said in a statement. “The addition of biological screening capabilities to our technology platform represents an exciting opportunity for our company.”
RTP-based ChemCodes’ proprietary chemistry technology platform addresses the chemistry bottleneck in drug discovery and development. ChemCodes is using this technology in collaboration with pharmaceutical and biotechnology companies to create enabling chemical synthesis solutions for the discovery and development of new medicinal compounds.